A Time-Resolved Fluorescence Immunoassay for the Measurement of Testosterone in Saliva: Monitoring of Testosterone Replacement Therapy with Testosterone Buciclate

Abstract

Monitoring of testosterone replacement therapy requires a reliable method for testosterone measurement. Determination of salivary testosterone, which reflects the hormone's biologically active plasma fraction, is a superior technique for this purpose. The aim of the present study was to establish a new sensitive time-resolved fluorescence immunoassay for the accurate measurement of testosterone levels in saliva and to validate it by monitoring testosterone replacement therapy in eight hypogonadal men.A clinical phase I-study with the new ester testosterone buciclate was performed to search for new testosterone preparations to produce constant serum levels in the therapy of male hypogonadism. After two control examinations eight male patients with primary hypogonadism were randomly assigned to two treatment groups (n= 2x4) and given single doses of either 200 mg (group I) or 600 mg (group II) testosterone buciclate intramuscularly. Saliva and blood samples were obtained 1, 2, 3, 5 and 7 days post injection and then weekly for three months.The time-resolved fluorescence immunoassay for salivary testosterone shows a detection limit of 16 pmol/l, an intra-assay CV of 8.9 % (at a testosterone concentration of 302 pmol/l), an inter-assay CV of 8.7 % (at a testosterone concentration of 305 pmol/l) and a good correlation with an established radioimmunsassay of r=0.89. The sample volume required by this method is only 180 µl for extraction and duplicate determination. The assay procedure requires no more than three hours.In group I (200 mg) testosterone did not increase to normal levels either in saliva or in serum. However, in group II, androgen levels increased significantly and were maintained in the normal range for up to 12 weeks with maximal salivary testosterone levels of 303 ±18 pmol/l (mean±SE) and maximal testosterone levels of 13.1 ±0.9 nmol/l (mean±SE) in serum in study week 6 and 7.The time-resolved fluorescence immunoassay for salivary testosterone provides a useful tool for monitoring androgen status in men and women and is well suited for the follow-up of testosterone replacement therapy on an outpatient basis. The long-acting ester testosterone buciclate is a promising agent for substitution therapy of male hypogonadism and in combination with testosterone monitoring in saliva offers an interesting new perspective for male contraception.

Testosterone levels in healthy men and the relation to behavioural and physical characteristics: facts and constructs

“…The same applies to determination of testosterone levels from saliva samples, which are correlated with free testosterone in serum. Reliable assays are still under development (204). Additional measurement of SHBG and its ratio to total testosterone is more reliable when estimating the bioavailable fraction of testosterone (198,205).…”

A highly sensitive immunofluorometric assay for the measurement of aldosterone in small sample volumes: validation in mouse serum

“…Sample extraction The serum sample (50 ml) collected from each animal was thawed and extracted using 2 ml dichloromethane (DCM)/polyethylene glycol 10 000 (PEG; 50 mg/l) according to a modified version of that described earlier (Tschop et al 1998). Each 50 ml sample was pipetted in a glass tube and vortexed at a low speed for 30 min and after the two phases separated, the organic phase (1 .…”

Best Practice No 170: Investigation of infertility with the emphasis on laboratory testing and with reference to radiological imaging

“…Clinicians may not be aware that clinical sampling using saliva for steroid measurements is practicable in some circumstances, [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36] including the measurement of oral progesterone. 25 In general, however, significant interindividual differences occur in saliva to serum ratios and these have not been investigated under the range of physiological and therapeutic conditions that may disturb them.…”